SMC approval welcome news for breast cancer patients
Trodelvy is accepted for use in mTNBC patients who have already received two or more systemic therapies
Read More
Tag: Trodelvy
Gilead and MSD collab on Trodelvy/Keytruda breast cancer trial
The companies will evaluate Trodelvy plus Keytruda for the first-line treatment of certain triple-negative breast cancer patients
Read More
Gilead’s Trodelvy scores accelerated approval in advanced bladder cancer
US Food and Drug Administration approved antibody drug conjugate based on Phase II trial results
Read More
Gilead to buy Immunomedics for $21bn
The move adds Trodelvy, a first-in-class antibody-drug conjugate approved to treat triple-negative breast cancer, to the drugmaker’s portfolio
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
